A Phase 2/3 Randomized Open-Label Study of Maintenance GRT-C901/GRT-R902 A Neoantigen Vaccine in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Neoplasms
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) For the vaccine production stage: A) Patients with histologically confirmed metastatic colorectal cancer who are planned for, or have received no more than 1 cycle of chemotherapy. B) Measurable and unresectable disease according to RECIST v1.1. C) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 2) For study treatment stage: A) Patients with histologically confirmed metastatic colorectal cancer who have been treated with fluoropyrimidine and oxaliplatin in combination with bevacizumab, have not experienced disease progression, and are receiving a fluoropyrimidine and bevacizumab as maintenance chemotherapy. B) ECOG performance status of 0 to 2

You may not be eligible for this study if the following are true:

  • 1) Patients with microsatellite instability-high disease. 2) Patient has a known tumor mutation burden <1 non-synonymous mutations/megabase. 3) Known DNA Polymerase Epsilon mutations and patients with known BRAFV600E mutations. 4) Known exposure to chimpanzee adenovirus within the prior 6 months, plan to receive a chimpanzee adenovirus-based vaccine in the next 6 months, and/or any history or anaphylaxis in reaction to a vaccination.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.